Tracers / [177Lu]Lu-DOTA-JR11

[177Lu]Lu-DOTA-JR11

Also written as [Lu-177]Lu-DOTA-JR11; Lu-177-DOTA-JR11
Radionuclide
Lu-177 t½ 9584.6 min
Modality
Therapy
Production route
Stage
Syntheses indexed
6

What it is

Compound class
Radiolabeled somatostatin receptor antagonist peptide (DOTA-conjugated)
Target / mechanism
Somatostatin receptor 2 (SSTR2) antagonist PMID 39149492
Clinical application
Theranostic pair

Regulatory status

FDA
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesismore than 95%DOTA-JR11
piCHEM, Raaba-Grambach, Austria
40147849
2025 J Nucl Med
Radiolabeling of the DOTA compounds was done at 85°C for 25 min, using ascorbic acid buffer and no-carrier-added [177Lu]LuCl3
Manual synthesis>95%>95%DOTA-JR11
CPC Scientific, San Jose, CA
39149492
2024 Res Sq
3.7 MBq (100 μCi) of ammonium acetate buffered [52Mn]MnCl2 (pH 4.5) was added to a 1.5 mL microcentrifuge tube containing 100 μL of 0.25 M ammonium acetate, pH 4.5, and varying concentrations of the ligands (0.1–1.0 nM). The reaction mixtures were incubated at 90°C while shaking for 30 min on a thermomixer (800 RPM). — DOTATATE and DOTA-JR11 were efficiently radiolabeled with > 95% RCY when ~ 5.6 nmol of each ligand was mixed with 3.7 MBq (100 μCi) of [52Mn]MnCl2
Manual synthesis99.096.6DOTA-JR1137389800
2023 EJNMMI Radiopharm Chem
The mixture was incubated for 20 min at 90 °C and then left to cool down for 5 min. — [177Lu]Lu-DOTA-JR1199.096.696.596.894.593.7
32859703
2021 J Nucl Med
42581163
2026 Eur J Nucl Med Mol Imaging
42185645
2026 Eur J Nucl Med Mol Imaging

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-JR11, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 7 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.